ABSTRACT
During infectious disease outbreaks, acquiring genetic data across various kingdoms offers essential information to tailor precise treatment methodologies and bolster clinical, epidemiological, and public health awareness. Metagenomics sequencing has paved the way for personalized treatment approaches and streamlined the monitoring process for both co-infections and opportunistic infections. In this study, we conducted long-read metagenomic DNA sequencing on Mpox-like lesion pustules in six suspected patients during the MPXV subclade Ib outbreak in Eastern Democratic Republic of the Congo. The sequenced data was taxonomically classified per the bacterial, fungal, and viral composition. Our results show a wide spectrum of microorganisms present in the lesions. Bacteria such as Corynebacterium amycolatum, Gardnerella vaginalis, Enterococcus faecium, Enterobacter clocae, Staphylococcus epidermidis, and Stenotrophomonas maltophilia were found in the lesions. The viral classification of the reads pointed out the absolute predominance of Monkeypox virus. Taken together, the outcomes of this investigation underscore the potential involvement of microorganisms in mpox lesions and the potential role that co-infections play in exacerbating disease severity and transmission during the MPXV subclade Ib outbreak.
Competing Interest Statement
The authors DJK, PK, AK, MD, and GSM are shareholders of the BioForge Canada Limited company. The company specializes in developing computational solutions for biological problems. The authors declare that the research reported in this work was conducted independently, and the reported results were not influenced by any financial or personal relationships with the company.
Funding Statement
This work was supported by awards from the Canadian Institutes of Health Research (CIHR), Mpox Rapid Research Funding Initiative (CIHR MZ1 187236), Research Nova Scotia Grant 2023-2565, Dalhousie Medical Research Foundation, and the Li-Ka Shing Foundation. DJK is the Canada Research Chair in Translational Vaccinology and Inflammation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance for conducting this study was approved by the Ethical Review Committee of the Catholic University of Bukavu (Number UCB/CIES/NC/022/2023). All study participants were introduced to the observational study and given the option to participate by providing informed consent or, in the case that the participant was a minor, parental permission or consent was obtained. In addition, we obtained written consent from the patient whose picture is shown in Figure 1.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
